As part of the French MitoDrug project, ebselen has shown efficacy in various preclinical models of Barth syndrome, and researchers have discovered that its mechanisms of action could be relevant to a broader range of mitochondrial diseases.
To identify compounds that could potentially treat Barth syndrome, teams involved in the French MitoDrug project screened a library of molecules that had already been evaluated in at least phase 2 clinical trials for various diseases, using yeast models of the condition. Among the molecules showing positive effects, ebselen proved to be one of the most active. The researchers subsequently confirmed its therapeutic potential in patient-derived cells and a mouse model of Barth syndrome—a potential that could extend to other mitochondrial diseases.
Positive effects of the drug in Barth syndrome…
The EMA’s positive opinion is based on preclinical studies and results from a Phase 2 clinical trial involving 39 patients, which suggest an improvement in motor function following treatment with Kygevvi®. However, given the rarity of TK2d, the laboratory cannot provide exhaustive data on the safety and efficacy of the treatment under normal conditions of use. Consequently, the EMA recommends that the MA be granted under “exceptional circumstances,” involving “specific obligations that will be reviewed annually.” In this spirit, the agency is also requiring UCB to conduct a new study to further confirm the efficacy and safety of Kygevvi®.

…and on various mitochondrial dysfunctions
In light of these observations, the researchers tested ebselen in yeast and a fungus models exhibiting various mitochondrial dysfunctions: abnormalities affecting respiratory chain complexes and the energy-producing complex, defects in mitochondrial DNA maintenance, and difficulties in synthesizing certain mitochondrial proteins. Here again, treatment improved the growth of these organisms, even though their growth depends on mitochondrial respiration and despite the fact that the genetic defect had not been corrected. Finally, these beneficial effects were confirmed in human cell models, including cardiomyocytes derived from a patient’s cells.
Hypotheses regarding ebselen’s mechanisms of action
Ebselen is an antioxidant and anti-inflammatory agent that is already being investigated in clinical trials for Ménière’s disease, which affects the inner ear and causes vertigo. However, through their work, the French researchers have demonstrated that other mechanisms of action are also involved in mitochondrial diseases.
On the one hand, ebselen appears to help reduce protein synthesis, which could allow the “diseased” cells to conserve energy while reducing their “stress”. On the other hand, it seems to improve the utilization of compounds generated by the breakdown of glucose by the Krebs cycle, which one fuels the series of reactions that ultmately lead to energy production by mitochondria. In other words, ebselen may not act solely on mitochondria. It may also promote the functional adaptation of cells to mitochondrial dysfunction.
A promising candidate
Finally, and importantly, ebselen has further advantage: its beneficial effects appear at very low doses in cell models, while the doses administered in mouse models have not caused any visible toxic effects. Of course, its safety in the context of mitochondrial diseases still requires further investigation, but in this respect, evaluations of ebselen in patients with other conditions are already providing valuable information. In conclusion, according to the French researchers, this treatment is “a promising candidate for therapeutic repurposing in Barth syndrome as well as in a wide range of inherited mitochondrial diseases.”
MitoScreen-MitoDrug-MitoComex, a French initiative
Thanks to the French MitoScreen project, conducted from 2016 to 2020, five potentially repurposable drugs, meaning drugs that had already been administered to humans and could prove effective in mitochondrial diseases, were identified.
Then, as part of MitoDrug, French researchers evaluated these five compounds, focusing on their beneficial effects on cardiac involvement, particularly in four groups of mitochondrial diseases: those associated with abnormalities in respiratory chain complex I, MELAS syndrome, disorders linked to the CHCHD10 gene, and Barth syndrome.
Finally, the MitoComex project aims to better understand the mecanisms of action of these drugs and, above all, to move to clinical trials in mitochondrial diseases.
AFM-Téléthon, which supported MitoScreen and MitoDrug, is now funding MitoComex.
Learn more
Ebselen restores mitochondrial function through metabolic rewiring in Barth syndrome and related mitochondrial diseases (scientific publication)